Key result
Multimodality testing identifies restrictive cardiomyopathy and constrictive pericarditis in HFpEF to guide targeted therapy.
Why the study?
A significant number of patients with suspected HFpEF have restrictive cardiomyopathy or chronic pericardial disease, and recognizing these syndromes early is needed to institute specific therapies that may improve survival and quality of life.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Patients with restrictive cardiomyopathies and constrictive pericarditis are often excluded or under-represented in large randomized clinical trials (2,5,6), making it difficult to make inferences from the prognostic and treatment features that apply to other HFpEF patients. Untreated, patients with restrictive cardiomyopathies have, in general, poor outcomes (7). However, early diagnosis can lead to improved symptoms, prevent end-organ damage, and improve survival.”
Advances in diagnostic imaging, biomarkers, and genetic testing help differentiate restrictive cardiomyopathy from constrictive pericarditis in patients with suspected HFpEF, enabling specific pharmacological, immunologic, and surgical therapies that improve quality of life and survival.
About one-half of the patients with congestive heart failure have preserved left ventricular ejection fraction (HFpEF). Although the etiology of HFpEF is most commonly related to long-standing hypertension and atherosclerosis, a significant number of suspected HFpEF patients have a restrictive cardiomyopathy or chronic pericardial disease. Recognizing these syndromes is important because early diagnosis may lead to instituting specific therapy that may prolong survival, improve quality of life, and/or recognize and treat an underlying systemic disorder. Advances in diagnostic imaging, biomarkers, and genetic testing today allow identification of the specific etiology in most cases. Novel pharmacological, immunologic, and surgical therapies are leading to improved quality of life and survival.
No takes yet. Share an insight, caveat, or question.
Mario Jorge Garcia (2016) conducted a review in Constrictive pericarditis, restrictive cardiomyopathy, and heart failure with preserved ejection fraction (HFpEF). Diagnostic imaging, biomarkers, genetic testing, and specific pharmacological, immunologic, and surgical therapies was evaluated. Diagnostic imaging, biomarkers, and genetic testing identify restrictive cardiomyopathy or constrictive pericarditis in patients with HFpEF (~50% of heart failure cases) to guide targeted therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: